GlobeNewswire Inc. · Jan 9, 2023
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company’s operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinical development programs and reducing its workforce, including the termination of most employees by the end of the first quarter.
GlobeNewswire Inc. · Nov 8, 2022
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
GlobeNewswire Inc. · Oct 3, 2022
Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation
GlobeNewswire Inc. · Sep 6, 2022
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY.
